Basilea Pharmaceutica AG
BPMUF
$71.00
-$0.60-0.84%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.11% | -7.65% | 35.40% | 20.13% | 75.71% |
| Total Other Revenue | 153.39% | 149.24% | 388.49% | 333.39% | 263.80% |
| Total Revenue | 6.74% | 4.99% | 49.38% | 32.53% | 83.35% |
| Cost of Revenue | 41.79% | 39.47% | 32.53% | 17.58% | -11.67% |
| Gross Profit | -26.24% | -27.44% | 84.82% | 63.97% | 15,231.59% |
| SG&A Expenses | 23.01% | 21.00% | 24.12% | 10.12% | 1.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.05% | 35.79% | 30.64% | 15.90% | -9.40% |
| Operating Income | -41.30% | -42.26% | 180.89% | 149.21% | 421.32% |
| Income Before Tax | -44.91% | -45.81% | 189.51% | 156.86% | 349.34% |
| Income Tax Expenses | 158.65% | 157.69% | 128.96% | 125.69% | -23,155.21% |
| Earnings from Continuing Operations | -52.75% | -53.53% | -16.46% | -25.89% | 368.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.75% | -53.53% | -16.46% | -25.89% | 368.03% |
| EBIT | -41.30% | -42.26% | 180.89% | 149.21% | 421.32% |
| EBITDA | -39.41% | -40.40% | 170.96% | 140.39% | 469.71% |
| EPS Basic | -53.32% | -54.08% | -17.87% | -26.83% | 366.05% |
| Normalized Basic EPS | -45.57% | -46.46% | 184.69% | 153.60% | 347.50% |
| EPS Diluted | -50.70% | -51.51% | -19.60% | -23.81% | 322.69% |
| Normalized Diluted EPS | -43.41% | -44.34% | 168.77% | 156.39% | 315.53% |
| Average Basic Shares Outstanding | 1.21% | 1.21% | 1.71% | 1.29% | 0.74% |
| Average Diluted Shares Outstanding | -2.64% | -2.64% | 7.71% | 0.19% | 15.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |